GlycoMimetics is a startup based in the United States, 1 tracked investor.
GlycoMimetics is a company headquartered in the United States. Brouky records 1 investor associated with the company.
GlycoMimetics is a biotechnology company developing glycomimetic therapeutics that target selectin-mediated cell adhesion to treat hematologic disorders and cancer; clinical-stage candidates have included uproleselan (GMI-1271) for acute myeloid leukemia and rivipansel (GMI-1070) for vaso-occlusive crises in sickle cell disease.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.